Acquisition signal Healix was acquired by Singlepoint Healthcare in June 2026, indicating a shift in ownership and potential strategic realignment. This creates an opportunity to engage the new parent company on scalable infusion management services and post-merger integration opportunities.

Infusion footprint As a national infusion services provider with physician-owned and ambulatory infusion centers across the United States, Healix has an established distribution network and client base that can be leveraged for cross-sell of related pharmaceutical formulations, workflow software, or bundled infusion services.

Tech stack leverage Current technologies include Avaya, Microsoft 365, Azure, Active Directory, DocuSign, VMware, WP Engine, and WeInfuse partnerships. This suggests readiness for scalable IT integrations, EDI/automation, and secure digital workflows to support enterprise-grade infusion operations for new and existing clients.

Strategic partnerships Past partnerships with WeInfuse and DoseMe indicate openness to software and precision dosing platforms. This presents a sales angle for enhanced software-enabled infusion management, dosing optimization, and IT-enabled compliance solutions to expand service offerings.

Growth potential Revenue range of 25–50 million with a mid-sized employee base signals room for expanding core services, adding manufacturing or compounding capabilities, and pursuing enterprise-level contracts with larger health systems or payors seeking infusion service scalability and reliability.